Therapeutic advances in Parkinson's disease

##plugins.themes.bootstrap3.article.main##

##plugins.themes.bootstrap3.article.sidebar##

PDF (Euskara)
Published 10-01-2020
DOI https://doi.org/10.1387/ekaia.20833
Maialen Duque
Farmakologia Saila. Medikuntza eta Erizaintza Fakultatea. Euskal Herriko Unibertsitatea (UPV/EHU)
Ainhoa Sagarduy
Farmakologia Saila. Medikuntza eta Erizaintza Fakultatea. Euskal Herriko Unibertsitatea (UPV/EHU)
Jorge E. Ortega
Farmakologia Saila. Medikuntza eta Erizaintza Fakultatea. Euskal Herriko Unibertsitatea (UPV/EHU)
Teresa Morera-Herreras
Farmakologia Saila. Medikuntza eta Erizaintza Fakultatea. Euskal Herriko Unibertsitatea (UPV/EHU)

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder related to age which prevalence is increasing, estimating that the cases will double in the next 40 years. Currently, among drugs available, L-dopa continues being the most effective therapy, but does not stop or slow down the degeneration. Moreover, its efficacy diminishes over time of treatment while mayor side effects appear, as dyskinesia. This review provides an overview of new therapeutic advances to treat PD, including serotonergic and glutamatergic drugs, pharmacokinetic optimizing pharmaceutical preparations or transcranial magnetic stimulation.

Abstract 389 | PDF (Euskara) Downloads 262

##plugins.themes.bootstrap3.article.details##

Keywords

Parkinson's disease, dyskinesia, L-dopa, serotonin, glutamate, pharmacokinetic

Issue
No. 36 (2019): EKAIA 36
Section
Ale Arrunta
(C) UPV/EHU Press
 
CC-BY-NC-SA